Cryo-Save Arabia’s lab, located in Dubai, is now U.S. Food and Drug Administration (FDA) registered for autologous and family-related use of umbilical cord blood stem cells. This important accreditation confirms again the quality and high standards that are key to Cryo-Save.
It is with great excitement that Cryo-Save Arabia, subsidiary of Europe’s leading family stem cell bank, has once again proven its quality and high standards in stem cell cryopreservation by receiving the FDA registration.
The U.S. Food and Drug Administration has a very strict approach to control the recovery, processing, storage, labeling, packaging and distribution of human cells and tissue-based products. Any registered establishments that provide cord blood products are subject to FDA inspection. The onsite assessment ensures that they are complying with the regulations designed to help guarantee the safety of processing cord blood and donor eligibility.
Mai Ibrahim, Lab Director of Cryo-Save Dubai, says “The U.S. FDA registration is great news for us, but also for our clients. It will assure them that we have disclosed all information about our company. We are determined to continue our commitment to the highest quality standards and thereby provide the best services to our customers.”
“We can be proud of the scientific experts operating in our laboratories. Once again, they have shown excellence in the quality of their work. Cryo-Save fairly deserves such accreditations as our foundation relies first on our professionalism,” added Arnoud van Tulder, CEO of Cryo-Save Group.
Cryo-Save Group has been active in the stem cell industry for more than 12 years. In its continuous efforts to reach and exceed internationally high standards, the company guarantees that all of its labs meet the highest quality criteria and are properly accredited. In addition to the American Association of Blood Banks (AABB) accreditation, the FDA record adds another milestone to Cryo-Save’s dedication to stem cell cryopreservation techniques and know-how.